Lp(a) and PCSK9 Inhibition in Nominally Controlled LDL-C Patients

Watch the video and learn on how to leverage incremental clinical benefit to patients with recent ACS and LDL-C near 70 mg/dL from optimized statin therapy and PCSK9i.

MAT-BH-2200017/v1/Jan 2022